Shanghai Allink Biotherapeutics Ltd. focus on the early discovery, clinical development and commercialization of bispecific antibody &bispecific antibody-drug conjugates (BsAb ADCs).
Total raised: $42M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.12.2024 | Series A | $42M | - |
Mentions in press and media 2
| Date | Title | Description |
| 02.12.2024 | Allink Biotherapeutics: $42 Million (Series A) Raised To Transform Bispecific Antibody And Antibody-Drug Conjugate Therapeutics | Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics, announced the completion of a $42 million Series A financing. The funding round wa... |
| - | Allink Biotherapeutics | “Shanghai Allink Biotherapeutics Ltd. focus on the early discovery, clinical development and commercialization of bispecific antibody &bispecific antibody-drug conjugates (BsAb ADCs).” |